乌帕替尼治疗度普利尤单抗抵抗的面颈部特应性皮炎1例  

Face Atopic Dermatitis Resistant to Dupilumab Successfully Treated with Upadacitinib:A Case Report

作　　者：陈教全 余南极 高爱莉[1] 熊斯颖[1] 赵晓岚[1] 叶倩如 杨艳[1] CHEN Jiaoquan;YU Nanji;GAO Aili;XIONG Siying;ZHAO Xiaolan;YE Qianru;YANG Yan(Department of Dermatology,Guangzhou Institute of Dermatology,Guangzhou 510095,China)

机构地区：[1]广州市皮肤病防治所皮肤科,广东广州510095

出　　处：《中国皮肤性病学杂志》2024年第7期772-774,共3页The Chinese Journal of Dermatovenereology

摘　　要：患者女,21岁,全身皮肤红斑、丘疹伴瘙痒8年。患者于外院诊断为特应性皮炎(AD),传统治疗欠佳。患者有过敏性鼻炎病史。实验室检查:过敏原特异性IgE 4607.00 IU/mL。患者接受12次的度普利尤单抗治疗后,躯干、四肢的皮损基本消退,瘙痒得到控制,但面颈部皮损无明显改善。停用度普利尤单抗并口服乌帕替尼治疗后,患者面颈部皮疹明显改善。A 21-year-old female presented with erythema,papules and pruritus for 8 years.She had been previously diagnosed with atopic dermatitis,but the conventional therapy had not been successful.The patient had a history of allergic rhinitis.Laboratory examination:allergen-specific IgE 4607.00 IU/mL.After receiving 12 rounds of treatment with dupilumab,the skin lesions on the trunk and extremities had subsided and the pruritus had been brought under control.However,the skin lesions on the face and neck were not significantly improved.After withdrawal of dupilumab and treatment with oral upadacitinib,the skin lesions on the face and neck were significantly improved.

关 键 词：特应性皮炎 度普利尤单抗 乌帕替尼 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]